


## PHARMACEUTICAL 2020



## Checkpoint Therapeutics Inc. Rank 215 of 358





## PHARMACEUTICAL 2020



## Checkpoint Therapeutics Inc. Rank 215 of 358

The relative strengths and weaknesses of Checkpoint Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Checkpoint Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 81% points. The greatest weakness of Checkpoint Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 61% points.

The company's Economic Capital Ratio, given in the ranking table, is 44%, being 7.6% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	26,966
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,119
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	136
Other Revenues	1,708
Property and Equipment	0
Research and Development	19,325
Selling, General and Administrative Expense	7,233

Output Variable	Value in 1000 USD
Assets	26,966
Liabilities	8,119
Expenses	26,558
Revenues	1,708
Stockholders Equity	18,847
Net Income	-24,714
Comprehensive Net Income	-24,714
Economic Capital Ratio	44%

